We read with great interest the Review by Cleynen and Vermeire (Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 496-503 [2012]).
1 As described by the authors, the outcomes of psoriatic lesions induced or exacerbated by anti-TNF agents are variable. Given that most of the evidence concerning this cutaneous reaction has been obtained from the rheumatological literature, 2-4 disagreement exists as to the need to suspend anti-TNF therapy to achieve complete resolution of these lesions in patients with IBD. Some studies 5, 6 (cited by Cleynen and Vermeire) report that the biologic agent should be maintained. On the other hand, the largest study 4 available on this topic reported that discontinuing anti-TNF therapy has been particularly successful in patients with IBD. However, these data must be interpreted with caution because anti-TNF withdrawal can worsen or reactivate symptoms of IBD. Furthermore, a limited number of patients with IBD were evaluated in these studies. [4] [5] [6] In this context, our group have conducted three systematic reviews to collect information on this paradoxical phenomenon specifically in patients with IBD. [7] [8] [9] To the best of our knowledge, the latest review 9 contains the largest number of patients with IBD and anti-TNF-related psoriatic lesions to date (n = 222). In this study, 9 we included data from 47 publications, including most of
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Rafael Denadai, Fábio V. Teixeira and Rogério Saad-Hossne the cohort studies 5, 6, 10 cited by the authors. Analysis of this data set demonstrated that patients with IBD who develop psoriatic lesions should be treated using a standard antipsoriatic therapy (for example, topical corticosteroids, emollients or keratolytic therapy) without discontinuing or switching their anti-TNF agent.
9 Discontinuation of anti-TNF therapy should be reserved for patients with lesions covering >5% of their body surface area or with lesions refractory to therapy, and when quality of life is severely impaired.
9 Physicians who deal with these patients should know this data to provide specific management. 
